Merck & Co (MRK)

During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average.

September 9, 2026 records indicate that Representative Maria Elvira Salazar filed a purchase of Merck & Co (NYSE:MRK), valued between $34,006 and $160,000. According to the September filing, the transaction occurred

Merck & Co., Inc. (NYSE:MRK) executives outlined a strategy centered on pipeline investment, new product launches and targeted business development as the company prepares for the eventual loss of exclusivity for KEYTRUDA. Chief Financial Officer Caroline Litchfield said Merck has increased its est

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Both have attracted considerable attention from Wall Street recently.

The company is coming back into the spotlight thanks to recent developments.

The Schwab US Dividend Equity ETF is a safe all-weather investment.

These 3 ETFs would give you a strong long-term portfolio to build from.

Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.